Search clinical trials for: SAR441000

Total 2 results

Sanofi
BioNTech RNA Pharmaceuticals GmbH

Terminated

A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Metastatic Neoplasm

France, Spain, United States, Belgium, Germany, Netherlands
Sanofi

Recruiting

Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors

Neoplasm

United States, Canada, China, Korea, Republic of, Singapore

3

Subscribe